- BGI Genomics Announces Pricing of Initial Public Offering
- BGI Launches the Latest Desktop Sequencer BGISEQ-50
- International Science Community Welcomes China National GeneBank Opening
- BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- The Evolution of Chronic Lymphocytic Leukemia Revealed
- BGI involved in publication of the first seahorse genome in Nature
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
- Mapping more genomes will create a healthcare 'big data revolution'
Tel: +86-755-36307212Email: email@example.com
Shenzhen, China– Recently, BGI announced that Dr. Leroy Hood, a world renowned scientist and genomics pioneer, has joined the company’s Scientific Advisory Board.
Dr. Hood, a pioneer in the systems approach to biology and medicine, is president and co-founder of the Institute for Systems Biology and senior vice president and chief scientific officer of Providence St. Joseph Health, based in Seattle.
Dr. Hood was involved in the development of five instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine.
In addition to his ground-breaking research, Dr. Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine.
As the member of BGI’s Scientific Advisory Board, Dr. Hood will devote efforts to provide professional advice based on his rich experience and insights in the field.
"BGI has enormous ambitions with a broad scope and expertise in many kinds of genomes, from humans to animals, plants and microbes,” Dr. Hood said in a statement. “I think they are absolutely right to push sequencing technology to its limit. I am interested in learning about BGI’s approaches to human health, and in finding our common interests to advance medicine.”
Dr. Yiwu He, BGI’s Global Head of Research & Development, said, “Dr. Hood is a world class leader in genomic sequencing and precision medicine. His vision and wisdom will add huge value to BGI’s efforts to solve healthcare problems with cutting-edge technologies and innovative solutions.”